Intelligence / Healthtech & medtech market map / Diagnostics and laboratory products / Molecular and specialised diagnostics / Rapid and point-of-care molecular testing for acute-care decisions
Rapid and point-of-care molecular testing for acute-care decisions
Compact, cartridge-based molecular systems used at the point of care or near the bedside (emergency departments, urgent care, intensive care, outpatient clinics) to return a syndromic result in minutes and support immediate isolation, antibiotic or admission decisions. Job to be done: shorten time-to-answer for acutely ill patients where a central-lab turnaround of hours is clinically unacceptable. Excludes central-lab routine panels and complex genomic testing.
- Level
- Niche
- Segmented by
- Customer type
- Buyers
- Hospital laboratories and acute-care departments, plus specialised diagnostic providers operating urgent-care and ambulatory sites
- Buying centre
- Hospital emergency/ambulatory operations leadership with clinical microbiology and infection-control sign-off; purchasing run through hospital supply chain or GPO contracts, often with per-test or per-cartridge pricing.
- Antimicrobial stewardship and sepsis-pathway targets that require rapid results
- Hospital-acquired infection and outbreak response protocols
- Shift of care into urgent care and ambulatory settings
- Reimbursement for syndromic panels and rapid respiratory testing
- High cost per test and cartridge wastage when run at low volume
- Reimbursement for rapid syndromic panels is inconsistent across payers
- Workflow and staff training burden of running molecular systems outside the central lab
- Need for connectivity and result integration with the LIS/EHR
How this was sized
$2.6B ($1.9B–$3.4B) · 2025 · Triangulated
Same USD 22.0B submarket pool as the other niches (see notes in niche 1). Rapid/point-of-care molecular assumed 12% of the submarket = USD 2.64B (range 1.9-3.4B). Forecast: 2,640 x 1.09^5 = USD 4,060M in 2030. 9.0% CAGR reflects faster growth than the 4.78% clinical diagnostics CAGR [1] and the 5.5% CAGR in [9], consistent with the shift of medtech into alternative care settings noted in [2]. Low confidence: no source in the set sizes point-of-care molecular directly; the 12% share is an assumption.
- Clinical Diagnostics Market Size, Share, Growth and Forecast, 2025-2035
credenceresearch.com · 2026-10-15 - EY Pulse of the MedTech Industry Report 2026 | EY - US
ey.com · 2026-10-19 - Global Diagnostic Tests Market Size, Share, Trends and Forecast 2026-2033
pheonixresearch.com · 2026-07-16 - Clinical Diagnostics Market Growth & Forecast 2026-2036
futuremarketinsights.com · 2026-11-02
Alongside it in Molecular and specialised diagnostics
// Sell into Rapid and point-of-care molecular testing for acute-care decisions